PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 14, 2006British Journal of Cancer340 citationsOpen Access

Towards third generation matrix metalloproteinase inhibitors for cancer therapy

COChristopher M. OverallOKO. Kleifeld

Key Points

Key points are not available for this paper at this time.

Abstract

The failure of matrix metalloproteinase (MMP) inhibitor drug clinical trials in cancer was partly due to the inadvertent inhibition of MMP antitargets that counterbalanced the benefits of MMP target inhibition. We explore how MMP inhibitor drugs might be developed to achieve potent selectivity for validated MMP targets yet therapeutically spare MMP antitargets that are critical in host protection.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Overall et al. (2006) studied this question.

synapsesocial.com/papers/6a74be9a0081fe7b05dbe78chttps://doi.org/10.1038/sj.bjc.6603043
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy2006 · 1,212 citations
  2. 2Mechanistic Basis of Enzyme-Targeted Drugs2005 · 249 citations
  3. 3Metastatic potential correlates with enzymatic degradation of basement membrane collagen1980 · 1,776 citations
  4. 4Impact of Mobility on Structure-Based Drug Design for the MMPs2002 · 51 citations
  5. 5Proteomic Validation of Protease Drug Targets: Pharmacoproteomics of Matrix Metalloproteinase Inhibitor Drugs Using Isotope-Coded Affinity Tag Labelling and Tandem Mass Spectrometry2006 · 38 citations